News
-
-
PRESS RELEASE
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Curatis Holding AG shareholders approve all proposals at Annual General Meeting including annual report and 2024 financial year. Details of re-elected board members and company focus on rare diseases -
-
PRESS RELEASE
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog
Curatis Holding AG reveals Corticorelin as active substance of C-PTBE-01, targeting larger patient group for PTBE treatment. Strengthened team with Dr. Kirsty Crame and Dr. Timm Trenktrog. Market opportunity in PTBE surpassing USD 1 billion -
-
-
-
-
-
PRESS RELEASE
Curatis wird für C-PTBE-01 in den USA eine Biologic License beantragen - damit erhöht sich die Dauer des Marktschutzes in den USA markant im Falle einer Zulassung
Curatis Holding AG plans to apply for a Biologic License (BLA) for C-PTBE-01 in the USA, extending market protection significantly if approved
